Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMO1D9E)

• Drug Name: VX-522 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Cystic fibrosis	CA25	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMO1D9E

Molecule-Related Drug Atlas

Drug(s) Targeting cAMP-dependent chloride channel (CFTR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ivacaftor	DMZC1HS	Cystic fibrosis	CA25	Approved	[3]
Crofelemer	DM4AMQZ	HIV-associated diarrhoea	1A2Z	Approved	[4]
Tezacaftor and ivacaftor	DMY62FC	Acute lung injury	NB32.3	Approved	[5]
VX-661	DMJBXO3	Cystic fibrosis	CA25	Phase 3	[6]
ABBV-2222	DM4ZLTY	Cystic fibrosis	CA25	Phase 2	[7]
GLPG-1837	DMOCRYB	Cystic fibrosis	CA25	Phase 2	[7]
iOWH032	DM5TMYC	Diarrhea	ME05.1	Phase 2	[8]
Lumacaftor	DMCLWDJ	Cystic fibrosis	CA25	Phase 2	[9]
QBW251	DMQ5APT	Chronic obstructive pulmonary disease	CA22	Phase 2	[10]
ABBV-3067	DMB01L5	Cystic fibrosis	CA25	Phase 1	[7]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
cAMP-dependent chloride channel (CFTR)	TTRLZHP	CFTR_HUMAN	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT05668741) A Phase 1 Single Dose Escalation Study Evaluating the Safety and Tolerability of VX-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and a CFTR Genotype Not Responsive to CFTR Modulator Therapy. U.S.National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Vertex
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [5] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [6] CFTR Modulators for the Treatment of Cystic Fibrosis. P T. 2014 Jul;39(7):500-11.
• [7] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [8] Developing novel antisecretory drugs to treat infectious diarrhea. Future Med Chem. 2011 Aug;3(10):1317-25.
• [9] A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med. 2014 Jul;2(7):527-38.
• [10] Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251). J Cyst Fibros. 2021 Mar;20(2):250-256.